Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.
Related to this article
Panelists explain why precision tools lag in schizophrenia care and highlight simple biomarkers, faster deals, and clinician-industry collaboration.
Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
Advertisement
Advertisement
Trending on Psychiatric Times
1
When to Switch Schizophrenia Treatment
2
ACNP Position Paper Lays Out Roadmap for Biomarker-Guided Psychiatric Drug Trials
3
Hippocampal Generative Processes During Sleep Support Rapid Learning of New Associations
4
Paganin October Cover Story References
5